Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in Lymphomas : Episode 7

CAR T-Cell Therapy for Patients With R/R FL

Feb 13, 2023

Loretta J. Nastoupil, MD
Marc S. Hoffman, MD

A discussion on which patients with relapsed/refractory follicular lymphoma are good candidates for CAR T-cell therapy.

EP: 1.Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

EP: 2.Currently Available Treatment Options for Patients With R/R DLBCL

EP: 3.ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL

EP: 4.Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?

EP: 5.Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL

EP: 6.Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)

EP: 7.CAR T-Cell Therapy for Patients With R/R FL

EP: 8.Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Related Videos

Meghan K. Berkenstock, MD

Ursula A. Matulonis, MD

Cara A. Mathews, MD

Dimitrios Nasioudis, MD, physician, fellow, gynecologic oncology, Department of Obsetrics and Gynecology, University of Pennsylvania, Penn Medicine

Lindsay K. Buckingham, MD, fellow, gynecologic oncology, Department of Obstetrics and Gynecology, University of North Carolina (UNC) Chapel Hill School of Medicine

Brian M. Slomovitz, MD

Shannon N. Westin, MD, MPH, FACOG

Pamela T. Soliman, MD, MPH

Meghan K. Berkenstock, MD

Ramez N. Eskander, MD

Related Content

Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC

March 31st 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

Liso-cel Receives European Approval Recommendation for Relapsed/Refractory LBCL

March 31st 2023

Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC

March 30th 2023

Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC

March 31st 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

Liso-cel Receives European Approval Recommendation for Relapsed/Refractory LBCL

March 31st 2023

Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC

March 30th 2023

Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC

March 31st 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

Liso-cel Receives European Approval Recommendation for Relapsed/Refractory LBCL

March 31st 2023

Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC

March 30th 2023

Related Content

The combination of tusamitamab ravtansine and pembrolizumab with or without chemotherapy generated responses and was well tolerated when used as first-line treatment for patients with CEACAM5-positive nonsquamous non–small cell lung cancer.

Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

$Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma$

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Niels Reinmuth, MD, PhD

Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC

March 31st 2023

$FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL$

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

Anne Kerber

Liso-cel Receives European Approval Recommendation for Relapsed/Refractory LBCL

March 31st 2023

Tamta Makharadze, MD

Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC

March 30th 2023

Latest Conference Coverage

Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases

Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC

Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.